2,244 reports of this reaction
1.8% of all TENOFOVIR DISOPROXIL FUMARATE reports
#15 most reported adverse reaction
OSTEOPENIA is the #15 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 2,244 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE to OSTEOPENIA. This represents approximately 1.8% of all 123,510 adverse event reports for this drug.
TENOFOVIR DISOPROXIL FUMARATE has an overall safety score of 85 out of 100. Patients taking TENOFOVIR DISOPROXIL FUMARATE who experience osteopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPENIA is a less commonly reported adverse event for TENOFOVIR DISOPROXIL FUMARATE, but still significant enough to appear in the safety profile.
In addition to osteopenia, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to osteopenia in FDA adverse event reports:
OSTEOPENIA has been reported as an adverse event in 2,244 FDA reports for TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPENIA accounts for approximately 1.8% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience osteopenia while taking TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.